COMMENT

ASPI: a public–private partnership to develop treatments for autism

Numerous potential therapeutic targets are being investigated in autism spectrum disorder (ASD). Here, we discuss a platform trial approach for designing proof-of-concept (POC) clinical studies of ASD — via the Autism Spectrum POC Initiative (ASPI) — that can be conducted through a public–private partnership with the aim of finding effective treatments in the most expeditious manner.
Janssen Research and Development, Titusville, NJ, USA.

Search for this author in:

Janssen Research and Development, Titusville, NJ, USA.

Search for this author in:

Janssen Research and Development, Titusville, NJ, USA.

Search for this author in:

Janssen Research and Development, Spring, TX, USA.

Search for this author in:

Janssen Research and Development, Titusville, NJ, USA.

Search for this author in:

Janssen Research and Development, Beerse, Belgium.

Search for this author in:

Department of Psychiatry and the Weill Institute for Neuroscience, University of California, San Francisco, CA, USA.

Search for this author in:

Department of Psychiatry and the Weill Institute for Neuroscience, University of California, San Francisco, CA, USA.

Search for this author in:

Department of Forensic & Neurodevelopmental Sciences, Institute of Psychiatry, King’s College London, UK.

Search for this author in:

Department of Psychiatry and Behavioral Sciences and Duke Institute for Brain Sciences, Duke University School of Medicine, Durham, NC, USA.

Search for this author in:

Janssen Research and Development, San Diego, CA, USA.

Search for this author in:

Janssen Research and Development, Titusville, NJ, USA.
Contact

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

doi: 10.1038/d41573-020-00012-4

References

  1. 1.

    Kanne S. M. et al. The Autism Impact Measure (AIM): initial development of a new tool for treatment outcome measurement. J. Autism Dev. Disord. 44, 168–179 (2014).

  2. 2.

    Ness S. L. et al. An Observational study with the Janssen Autism Knowledge Engine (JAKE®) in individuals with autism spectrum disorder. Front. Neurosci. 13, 111 (2019).

  3. 3.

    Berry, S. M. et al. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 313, 1619–1620 (2015).

Download references

Competing Financial Interests

S.N., G.P., S.J., K.W., A.B., N.V.M., W.C.D. and H.M. are employees of Janssen Research & Development and hold company stocks/stock options. H.M. reports a patent, which is assigned to Icahn School of Medicine at Mount Sinai, Yale University, and NIH; no financial benefit was received from this patent. R.H. received reimbursement for consultation from Janssen Research & Development. B.L. has received research grant funding from the NIH, is a consultant to Janssen Research & Development, the Illinois Children’s Healthcare Foundation and is a board member of the Brain Research Foundation. D.M. is on the Scientific Advisory Board of Roche. G.D. is on the Scientific Advisory Boards of Janssen Research & Development, Akili, LabCorp, Tris Pharm and Roche, a consultant for Apple, Gerson Lehrman Group, and Axial Ventures, has received grant funding from Janssen Research and Development and is CEO of DASIO. She receives royalties from Guilford Press, Springer and Oxford University Press.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.